Trial Profile

Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia: A Phase I Study (AflacLL1401)

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dasatinib (Primary) ; Cytarabine; Cytarabine; Fludarabine; Idarubicin
Indications Myeloid leukaemia
Focus Adverse reactions

Most Recent Events

17 Apr 2018 Planned End Date changed from 1 Feb 2018 to 15 Dec 2017.
17 Apr 2018 Planned primary completion date changed from 1 Feb 2018 to 15 Dec 2017.
17 Apr 2018 Status changed from recruiting to withdrawn prior to enrolment.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com